Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 29 Carcinoma, Non-Small-Cell Lung 29 Urinary Bladder Neoplasms 26 Neoplasms 22 Carcinoma, Renal Cell 22 Carcinoma, Merkel Cell 21 Neoplasm Metastasis 18 Colorectal Neoplasms 16 Breast Neoplasms 16 Squamous Cell Carcinoma of Head and Neck 15 Ovarian Neoplasms 14 Triple Negative Breast Neoplasms 11 Pancreatic Neoplasms 9 Melanoma 9 Head and Neck Neoplasms 8 Stomach Neoplasms 7 Recurrence 6 Carcinoma, Hepatocellular 6 Ureteral Neoplasms 5 Small Cell Lung Carcinoma 5 Prostatic Neoplasms 5 Urethral Neoplasms 4 Sarcoma 4 Neuroendocrine Tumors 4 Leukemia, Myeloid, Acute 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Turcot syndrome 3 Skin Neoplasms 3

Interventions

pembrolizumab 2 enfortumab vedotin 2 Gemcitabine 2 Carboplatin 2 zimberelimab 1 sirtratumab vedotin 1 sacituzumab govitecan 1 olaparib 1 avelumab 1 Oxaliplatin 1 Nivolumab 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Metastatic Urothelial Cancer × avelumab × Clear all

NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting

827 enrolled 1 FDA

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡